Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2)
作者:Ann Kathrin Strunz、Annelien J.M. Zweemer、Christina Weiss、Dirk Schepmann、Anna Junker、Laura H. Heitman、Michael Koch、Bernhard Wünsch
DOI:10.1016/j.bmc.2015.02.019
日期:2015.7
reaction using polymer-bound PPh3. In radioligand binding assays the spirocyclic butanamides 4 did not displace the iodinated radioligand 125I-CCL2 from the human CCR2. However, in the Ca2+-flux assay using human CCR2 strong antagonistic activity of butanamides 4 was detected. Analysis of the IC50-values led to clear relationships between the structure and the inhibition of the Ca2+-flux. 4g (4-(3
趋化因子CC受体亚型2(CCR2)的激活在慢性炎症过程中发挥重要作用,例如动脉粥样硬化,多发性硬化和类风湿性关节炎。通过螺环哌啶8的不同组合制备了多种螺环丁酰胺4(N-苄基-4-(3,4-二氢螺[[2]苯并吡喃-1,4'-哌啶] -1'-基)丁酰胺)(3,4-二氢螺[[2]苯并吡喃-1,4'-哌啶])和γ-卤代丁酰胺11。合成螺环哌啶8的关键步骤是β-苯基乙醇5与哌啶酮缩醛6的Oxa-Pictet-Spengler反应。取代的γ-羟基丁酰胺11c –通过用硫酸亚乙酯将乙酸甲酯13羟乙基化制备γ-内酯14c和14e来制备e。用苄胺对γ-内酯14c和14e进行氨解,得到γ-羟基丁酰胺15c - e,并通过与聚合物结合的PPh 3的Appel反应将其转变为溴化物11c - e。在放射性配体结合测定中,螺环丁酰胺4并未取代人CCR2中的碘化放射性配体125 I-CCL2。但是,在Ca 2+中使用人